Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 10128
    5. ›
  5. LAUREN SCIENCES LLC

LAUREN SCIENCES LLC

Company claim

Is this your business?

Get access!

Company Details

Name: LAUREN SCIENCES LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 23 Jun 2010 (15 years ago)
Entity Number: 3965091
ZIP code: 10128
County: New York
Place of Formation: New York
Address: 345 EAST 94TH STREET, SUITE 18A, NEW YORK, NY, United States, 10128

DOS Process Agent

Name Role Address
LAUREN SCIENCES LLC DOS Process Agent 345 EAST 94TH STREET, SUITE 18A, NEW YORK, NY, United States, 10128

U.S. Small Business Administration Profile

Phone Number:
212-737-0455
E-mail Address:
srosenbaum@laurensciences.com
Contact Person:
SUSAN ROSENBAUM
Ownership and Self-Certifications:
Economically Disadvantaged Women-Owned Small Business, Women-Owned Small Business, Woman Owned
User ID:
P1572439

Unique Entity ID

Unique Entity ID:
Z9REXXRSNLX8
CAGE Code:
6HTA4
UEI Expiration Date:
2026-05-01

Business Information

Activation Date:
2025-05-08
Initial Registration Date:
2011-08-29

Commercial and government entity program

CAGE number:
6HTA4
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-05-08
CAGE Expiration:
2030-05-08
SAM Expiration:
2026-05-01

Contact Information

POC:
SUSAN ROSENBAUM

History

Start date End date Type Value
2010-06-23 2016-06-21 Address 71 EAST 77TH STREET, SUITE 8A, NEW YORK, NY, 10075, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
200721060094 2020-07-21 BIENNIAL STATEMENT 2020-06-01
160621006217 2016-06-21 BIENNIAL STATEMENT 2016-06-01
120613006333 2012-06-13 BIENNIAL STATEMENT 2012-06-01
100831000736 2010-08-31 CERTIFICATE OF PUBLICATION 2010-08-31
100628000454 2010-06-28 CERTIFICATE OF CHANGE 2010-06-28

USAspending Awards / Financial Assistance

Date:
2022-08-20
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
LAUR-201 (V-SMART?-TNV FOR NEURO-HIV): NOVEL V-SMART? NANOMEDICINE FOR TREATMENT OF HAND - LAUREN SCIENCES GOAL IS TO ADVANCE DEVELOPMENT OF ITS INNOVATIVE V-SMART® NANOMEDICINE FOR NEURO-HIV, LAUR- 201 (V-SMART®-TENOFOVIR FOR NEURO-HIV), AS A DISEASE-MODIFYING THERAPEUTIC FOR THE CRITICAL UNMET MEDICAL NEEDS OF 50% OF THE 40 MILLION HIV PATIENTS WORLDWIDE WHO, DESPITE SUPPRESSIVE ANTIRETROVIRAL THERAPY (ART), SUFFER FROM HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND). CURRENTLY, THERE ARE NO FDA-APPROVED THERAPIES FOR HAND, AND CLINICAL SYMPTOMS INCLUDE QUANTIFIABLE COGNITIVE DEFICITS HALLMARKED BY IMPAIRED MEMORY. A MAJOR SHORTCOMING OF FIRST-LINE HIV THERAPIES IS LACK OF SUSTAINED POTENT DELIVERY TO THE CENTRAL NERVOUS SYSTEM (CNS), WHICH LAUR-201 IS DESIGNED TO SOLVE. TENOFOVIR (TNV), A COMPONENT OF FIRST-LINE COMBINATION ANTIRETROVIRAL (ARV) PILLS TRUVADA AND ATRIPLA, IS WIDELY USED AND EFFECTIVE IN HIV-INFECTED INDIVIDUALS; HOWEVER, TNV HARDLY CROSSES THE BLOOD BRAIN BARRIER (BBB). SINCE TNV HAS THE POOREST BBB PENETRATION OF TYPICAL ARV DRUGS, AND IS CONTAINED IN THE MOST WIDELY PRESCRIBED FIRST-LINE THERAPY REGIMENS, DELIVERING TNV INTO THE CNS MAY BE THE MOST USEFUL TO ELIMINATE HIV IN THE CNS. TNV IS PARTICULARLY EFFECTIVE IN PENETRATING AND ELIMINATING HIV FROM THE PREDOMINANT CELLS HARBORING HIV IN THE BRAIN, AND ONGOING LOW-LEVEL VIRAL REPLICATION IN THE BRAIN CONFERS A UNIQUE SANCTUARY FOR HIV, WHICH FURTHER CONTRIBUTES TO HAND PATHOGENESIS AND THE CNS HIV RESERVOIR. LAUREN SCIENCES USED ITS NOVEL CUTTING EDGE V-SMART® PLATFORM TO DEVELOP LAUR-201, PROVEN IN PRELIMINARY DATA TO: (1) ENCAPSULATE HIGH TNV CONCENTRATIONS, (2) RETAIN TNV CHEMICAL STRUCTURE, (3) DELIVER THERAPEUTIC TNV CONCENTRATIONS INTO MOUSE BRAIN AFTER SYSTEMIC ADMINISTRATION, WITHOUT APPARENT TOXICITY, AND (4) REACH TNV BRAIN LEVELS IN MICE WELL ABOVE THOSE ATTAINED IN ART-TREATED PATIENTS’ BLOOD. THIS SBIR PHASE I IS CRITICAL TO PROVE FEASIBILITY OF LAUR-201 TO: (1) MAINTAIN TNV EFFICACY IN VITRO AND THERAPEUTIC LEVELS IN MICE BRAIN, AND (2) BE EFFECTIVE IN THE MURINE HAND MODEL, I.E., SUPPRESS PERSISTENT HIV IN THE CNS AND AMELIORATE COGNITIVE DEFICITS CONFERRED BY HIV, WITHOUT TOXICITY, COMPARED TO FREE TNV, AFTER SYSTEMIC ADMINISTRATION. LAUR-201 IS A BREAKTHROUGH SOLUTION FOR HAND, SOLVES THE TNV BRAIN DELIVERY ISSUE, TARGETS PERSISTENT HIV WITHIN THE CNS AND CAN IMPACT, AND EXERT A SUSTAINED, POWERFUL INFLUENCE ON, THIS HIGH UNMET MEDICAL NEED. LAUR-201 IS INTENDED TO BECOME THE FIRST FDA-APPROVED DRUG TO SAFELY PREVENT HAND AND OVERCOME NEURO-HIV AS PART OF THE STANDARD TREATMENT FOR HIV PATIENTS.
Obligated Amount:
599979.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
86945325
Mark:
V-SMART
Status:
SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED
Mark Type:
TRADEMARK
Application Filing Date:
2016-03-18
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
V-SMART
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Pharmaceutical preparations for the targeted treatment of diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, and pharmaceutical preparations for the treatment of cancer, central nervous system and neurologica...
First Use:
2017-07-23
International Classes:
005 - Primary Class
Class Status:
Active
Serial Number:
87614253
Mark:
TO LIVE WELL, GIVE WELL
Status:
SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED
Mark Type:
SERVICE MARK
Application Filing Date:
2017-09-19
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
TO LIVE WELL, GIVE WELL
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
drug development services; development of pharmaceutical preparations for the targeted treatment of diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, and pharmaceutical preparations for the treatment of canc...
First Use:
2017-09-17
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
87555042
Mark:
PATIENTS ARE WAITING, BUT THEY CAN'T WAIT PATIENTLY
Status:
PARTIAL SECTION 8 & 15 ACCEPTED AND ACKNOWLEDGED
Mark Type:
SERVICE MARK
Application Filing Date:
2017-08-03
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
PATIENTS ARE WAITING, BUT THEY CAN'T WAIT PATIENTLY
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
[charitable fundraising]
First Use:
2017-08-01
International Classes:
036 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
drug development services; development of pharmaceutical preparations for the targeted treatment of diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, and pharmaceutical preparations for the treatment of canc...
First Use:
2017-08-01
International Classes:
042 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

345 EAST 94TH STREET, SUITE 18A, NEW YORK, NY, United States, 10128

LAUREN BIOTECH LLC

Date of last update: 27 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated